PODD
FY2026 Q1 · Calendar Q2 2026
Insulet Corp.
Insulet delivered a strong Q1 with 30% YoY revenue growth, beating EPS by 19% and revenue by 4%, and raised full-year guidance from 20-22% to 21-23%. Yet the stock dropped 11% on heavy volume. The disconnect reflects concerns about a $10M revenue timing shift from early distributor ordering, seasonal lumpiness from deductible resets, and competitive pressures in the pharmacy channel rather than the headline results. Management remains confident, backed by the Libre 3 Plus integration unlocking 450,000 potential users, algorithm improvements lifting time-in-range by approximately 5%, and a pipeline led by Omnipod 6 (2027) and the EVOLVE closed-loop system. The key question is whether 20%+ growth is sustainable as the base scales and competition intensifies.
EPS surprise+19.3%
Market move-9.7%
